Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 4Recruiting 2Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 360Neoplasms 255Carcinoma, Non-Small-Cell Lung 199Colorectal Neoplasms 183Lung Neoplasms 152Prostatic Neoplasms 151Carcinoma, Hepatocellular 128Leukemia, Myeloid, Acute 96Pancreatic Neoplasms 86Multiple Myeloma 84Neoplasm Metastasis 74Recurrence 71Uterine Cervical Neoplasms 69Rectal Neoplasms 68Stomach Neoplasms 65Ovarian Neoplasms 65Triple Negative Breast Neoplasms 60Squamous Cell Carcinoma of Head and Neck 57Head and Neck Neoplasms 54Glioblastoma 54Brain Neoplasms 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Small Cell Lung Carcinoma 50Endometrial Neoplasms 47Melanoma 44Esophageal Neoplasms 43Disease 43Colonic Neoplasms 42Hematologic Neoplasms 41Glioma 40

Interventions

ribociclib 1exemestane 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Letrozole 1Drug Therapy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Anatomic Stage II Breast Cancer AJCC v8 × 1 year × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡